Physician profile
James E Dello Russo
NPI 1306856091
$3,917.61
in general payments reported to CMS, 2019-2025
20 companies · $618 in 2025
The $618 reported for 2025 was more than what 82% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $341 · 2021: $579 · 2022: $419 · 2023: $843 · 2024: $995 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,439 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,438.82 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $701.56 | 2019-2025 | Cequa |
| Alcon Vision LLC | $696.22 | 2019-2025 | Clareon, Centurion, Precision 1 |
| Allergan, INC. | $423.18 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $325.44 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $322.95 | 2019-2023 | |
| Harrow Eye, LLC | $285.75 | 2024-2025 | Vevye |
| Abbvie INC. | $264.85 | 2022-2025 | Lumigan, Durysta, Vuity |
| Bausch & Lomb Americas INC. | $197.20 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Dompe US, INC. | $174.90 | 2021-2025 | Oxervate |
| Oyster Point Pharma, INC. | $122.47 | 2022-2025 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $97.96 | 2021-2022 | |
| Coopervision INC. | $97.23 | 2021-2024 | Biofinity Contact Lens, Misight Contact Lens |
| Eyevance Pharmaceuticals LLC | $75.73 | 2020-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $29.56 | 2021 | |
| Shire North American Group INC | $23.86 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $17.93 | 2024 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Horizon Therapeutics Plc | $17.28 | 2023 | Tepezza |
| Mallinckrodt Enterprises LLC | $15.32 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $14.34 | 2019 | |
| Aerie Pharmaceuticals, INC. | $13.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Dello Russo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.